Pharma and biotech stocks

125 companies in this theme

CompanyPriceChangeMarket capP/EDividend
Eli LillyLLY$1,415.55−1.13%$1.28T46.50.5%
Johnson & JohnsonJNJ$278.70−1.36%$680.19B42.91.9%
AbbVieABBV$292.82−0.59%$517.59B50.42.4%
Roche HoldingROPCHF 406.20−0.76%CHF 325.56B26.72.4%
Merck & Co.MRK$143.37−0.75%$356.13B144.52.4%
NovartisNOVN · SIXCHF 133.28−1.83%CHF 256.4B32.62.8%
AstraZenecaAZN · LSE13,802.00 GBp−1.65%£217.66B26.61.7%
AmgenAMGN$457.93−0.95%$250.07B26.82.2%
Gilead SciencesGILD$170.26+1.60%$211.18B—1.9%
Novo NordiskNOVO.B · Nasdaq Copenhagenkr 275.50−3.42%kr 1.26T11.24.2%
PfizerPFE$28.47−1.35%$164.5B41.26.0%
Vertex PharmaceuticalsVRTX$534.20−0.67%$135.44B34.4—
Bristol-Myers SquibbBMY$61.35−2.51%$125.4B13.64.1%
SanofiSAN · Euronext Paris€86.56−1.99%€106.04B25.54.8%
GSKGSK · LSE1,869.00 GBp−3.14%£77.35B18.03.7%
Regeneron PharmaceuticalsREGN$957.76+0.56%$98.52B21.10.4%
ModernaMRNA$206.80−3.93%$87.1B——
MerckMRK€150.75+0.70%€65.09B33.91.5%
CSLCSL$198.54−0.51%$95.48B—2.0%
BayerBAYN€56.14−1.51%€56B—0.2%
UCBUCB€286.80−2.81%€55.69B25.70.5%
argenxARGX · NASDAQ$947.52−0.36%$59.8B32.9—
Galderma GroupGALDCHF 187.15−2.02%CHF 43.64B64.50.2%
Teva Pharmaceutical IndustriesTEVA$42.62+0.12%$49.67B99.0—
Samsung Biologics207940₩1,381,000.00−2.33%₩65.83T31.2—
Sun Pharmaceutical IndustriesSUNPHARMA · NSE₹1,880.00−0.27%₹4.48T40.90.9%
BeOne MedicinesONC · NASDAQ$413.26+0.48%$46.98B52.7—
HaleonHLN · LSE342.30 GBp−1.27%£30.43B19.32.1%
Royalty PharmaRPRX$68.68+0.23%$39.4B45.41.4%
BiogenBIIB$250.79−0.34%$37.07B107.2—
Celltrion068270₩208,500.00−2.11%₩48.81T31.40.3%
ZoetisZTS$83.48−1.08%$33.92B14.12.5%
GenmabGMAB · Nasdaq Copenhagenkr 3,502.00−0.77%kr 214.45B46.2—
InsmedINSM$121.86−0.83%$26.96B——
Hansoh Pharmaceutical Group3692$32.42−2.99%$202.62B27.61.5%
United TherapeuticsUTHR$584.10−0.64%$25.04B22.2—

Pharma and biotech at a glance

Pharmaceutical and biotechnology companies research, develop and sell medicines, from large drug makers to smaller biotech firms with a few products in development.

Results depend on clinical trial outcomes, regulatory approvals and patent expiries, when generic competitors arrive. Large groups often pay dividends; young biotech companies rarely do.